With smaller sample sizes, benefits of bilingual experience may only be evident in older participants (see Bialystok et al., 2004).
Due to the methodological approach of a pilot study, including a limited sample size, objective benefits of routine HRQoL assessment, as well as generalisability of the participants' statements, need to be confirmed within a larger controlled study.
Studies that examine risk factors for nosocomial CDI, particularly in the setting of limited sample size, may benefit from the use of CDS-ID to summarize risk of CDI associated with the degree of underlying comorbidity.
Weaknesses of the study included the short time horizon, lack of healing and pain data, small sample size, awkward benefit units, and no consideration of healing rate changes in the sensitivity analysis.
As noted previously in a similar analysis by Lindquist et al. (2013), increasing sample size can benefit genome-wide power more than increasing array density even up to full genotyping of the complete 1000 Genomes variant set.
The ENBS provides a necessary and sufficient condition for deciding to conduct more research that is, if the ENBS is greater than zero for any sample size then the benefits of gathering the sample information exceed the costs, and further research is potentially justified.
Exclusion of individuals prior to analysis is a trade-off between loss of power due to reduced sample size, and the benefit of controlling the number of false positives.
7 10 Although many surgeons perform IVB before vitrectomy in patients with diabetes, systematic or larger sample size studies demonstrating its benefits in facilitation of surgery and clinical outcomes are limited.
We find that the data clustering using a small sample size provides significant performance benefit while only incurring a very small computation and memory cost.
In the future, integrating sequence information from DNASeq and RNASeq as well as clinical information in bigger sample size data sets may benefit such purpose.
Our analysis, with larger sample size, showed a significant benefit of everolimus eluting stents over paclitaxel eluting stents for target vessel revascularisation and target lesion revascularisation (rate ratio 0.68 (95% credibility interval 0.44 to 0.95) and 0.60 (0.33 to 0.93), respectively).
